Pfizer (PFE) Upgraded to “Buy” at ValuEngine
ValuEngine upgraded shares of Pfizer (NYSE:PFE) from a hold rating to a buy rating in a research note published on Tuesday morning.
A number of other research firms have also recently commented on PFE. Morningstar set a $46.00 price objective on Pfizer and gave the company a neutral rating in a research report on Tuesday. Independent Research set a $48.00 price target on Pfizer and gave the stock a neutral rating in a research note on Thursday, October 4th. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the stock a buy rating in a research note on Thursday, October 4th. Barclays reaffirmed a neutral rating and issued a $40.00 price target on shares of Pfizer in a research note on Wednesday, September 26th. Finally, JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the stock a buy rating in a research note on Monday, October 1st. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have assigned a buy rating to the company. Pfizer has a consensus rating of Hold and a consensus target price of $42.40.
Pfizer stock opened at $43.78 on Tuesday. The company has a market capitalization of $262.34 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96. Pfizer has a 12 month low of $33.20 and a 12 month high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
In other Pfizer news, VP Loretta V. Cangialosi sold 26,814 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the transaction, the vice president now owns 102,360 shares of the company’s stock, valued at $4,110,777.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sally Susman sold 40,381 shares of the business’s stock in a transaction on Friday, July 20th. The stock was sold at an average price of $37.22, for a total value of $1,502,980.82. Following the transaction, the insider now directly owns 155,377 shares in the company, valued at approximately $5,783,131.94. The disclosure for this sale can be found here. Insiders have sold 761,230 shares of company stock worth $29,054,690 in the last three months. 0.06% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. HC Financial Advisors Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $2,685,000. Wall Street Access Asset Management LLC lifted its stake in shares of Pfizer by 54.8% in the 4th quarter. Wall Street Access Asset Management LLC now owns 27,695 shares of the biopharmaceutical company’s stock valued at $1,002,000 after purchasing an additional 9,801 shares during the last quarter. Halsey Associates Inc. CT lifted its stake in shares of Pfizer by 67.9% in the 4th quarter. Halsey Associates Inc. CT now owns 46,640 shares of the biopharmaceutical company’s stock valued at $1,689,000 after purchasing an additional 18,868 shares during the last quarter. APCM Wealth Management for Individuals acquired a new position in shares of Pfizer in the 4th quarter valued at $684,000. Finally, Banco de Sabadell S.A acquired a new position in shares of Pfizer in the 4th quarter valued at $11,701,000. 68.95% of the stock is currently owned by institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: What are earnings reports?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.